Comparison Study of Transversus Abdominal Plane, Paravertebral and Epidural Blocks in Laparoscopic Colectomy

NCT02164929 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2017-09-25

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the effectiveness of transversus abdominal plane (TAP) block, thoracic epidural or paravertebral block (PVB) for controlling postoperative pain when compared with opioid you self-administer in your vein using a PCA device. The primary outcome will be postoperative opioid consumption within 24 hours after surgery. A total of 120 subjects will be randomized in a 1:1:1:1 ratio to receive a TAP block, PVB, TEA or no block (PCA alone).Patients in all groups will be cared for using an established enhanced recovery after surgery (ERAS) pathway incorporating a multimodal analgesic regimen using IV acetaminophen and postoperative PCA fentanyl.

Conditions

  • Laparoscopic Colorectal Resection

Interventions

PROCEDURE

TAP block

PROCEDURE

Epidural

PROCEDURE

Paravertebral block

DRUG

Acetaminophen 1g IV

DRUG

Dexamethasone 4mg

DRUG

Midazolam up to 2mg

DRUG

Propofol 1-2.5 mg/kg

DRUG

Sevoflurane to keep a bispectral index of between 40-60

DRUG

Local infiltration with 10 mL of plain ropivacaine 0.25%

DRUG

Lidocaine

1.5% lidocaine

DRUG

Epinephrine

1:200,000 epinephrine

DRUG

Hydromorphone

400-800 mcg Hydromorphone will be given preoperatively

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02164929 on ClinicalTrials.gov